Instituto de Investigaciones Biomédicas Alberto Sols-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2024

  1. Correction to: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells (British Journal of Cancer, (2024), 130, 8, (1402-1413), 10.1038/s41416-024-02649-z)

    British Journal of Cancer

  2. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells

    British Journal of Cancer, Vol. 130, Núm. 8, pp. 1402-1413

2021

  1. Multiplexed Biosensing Diagnostic Platforms Detecting Autoantibodies to Tumor-Associated Antigens from Exosomes Released by CRC Cells and Tissue Samples Showed High Diagnostic Ability for Colorectal Cancer

    Engineering, Vol. 7, Núm. 10, pp. 1393-1412

  2. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

    Biomedicine and Pharmacotherapy, Vol. 144

2020

  1. Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis

    Journal of Proteomics, Vol. 214

  2. Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform

    Theranostics, Vol. 10, Núm. 7, pp. 3022-3034

2019

  1. The specific seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein

    Scientific reports, Vol. 9, Núm. 1, pp. 13547

2016

  1. Toward liquid biopsy: Determination of the humoral immune response in cancer patients using halotag fusion protein-modified electrochemical bioplatforms

    Analytical Chemistry, Vol. 88, Núm. 24, pp. 12339-12345